-
公开(公告)号：US20140187552A1
公开(公告)日：2014-07-03
申请号：US13951642
申请日：2013-07-26
IPC分类号： A61K31/5377
CPC分类号： A61K31/5377 , A61K31/00
摘要： The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity.
摘要翻译： 本发明包括通过显示D2和D5组合的拮抗活性的药物治疗侵略和类似行为综合征的方法，例如冲动和易激惹。
-
公开(公告)号：US20230102784A1
公开(公告)日：2023-03-30
申请号：US17896774
申请日：2022-08-26
IPC分类号： A61K31/5375 , A61K31/00
摘要： The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
-
公开(公告)号：US11166960B2
公开(公告)日：2021-11-09
申请号：US17238796
申请日：2021-04-23
发明人： Padmanabh P. Bhatt , Argaw Kidane , Kevin Edwards
摘要： Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
-
公开(公告)号：US20210308142A9
公开(公告)日：2021-10-07
申请号：US17081383
申请日：2020-10-27
发明人： Padmanabh P. BHATT , Argaw KIDANE , Kevin EDWARDS
摘要： Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
-
公开(公告)号：US20210038613A1
公开(公告)日：2021-02-11
申请号：US17081383
申请日：2020-10-27
发明人： Padmanabh P. BHATT , Argaw KIDANE , Kevin EDWARDS
摘要： Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
-
公开(公告)号：US20200262789A1
公开(公告)日：2020-08-20
申请号：US16863020
申请日：2020-04-30
发明人： Martin Hanbauer , Zarghun Nazir , Peter Hildebrand , Attilia Figini , Likan Liang , Tiziano Fumagalli
IPC分类号： C07D209/08 , C07D295/13
摘要： The present invention is directed towards novel methods of synthesis of molindone, synthesis of the intermediates of molindone, and high-purity compositions of molindone. In particular, the invention relates to the methods of synthesis of molindone through the Mannich reaction.
-
47.发明申请公开(公告)号：US20200246348A1
公开(公告)日：2020-08-06
申请号：US16851980
申请日：2020-04-17
IPC分类号： A61K31/5377 , G16H10/20 , G16H50/30 , G16H50/20
摘要： The present disclosure relates to the treatment of impulsive aggression with molindone as an add-on therapy where patients are already receiving treatment for the underlying disease or disorder, e.g. attention deficit hyperactivity disorder (ADHD), bipolar disorder, autism, Tourette's syndrome or post traumatic stress disorder (PTSD), using evidence-based impulsive aggression testing methodologies and systems.
-
公开(公告)号：US20200022986A1
公开(公告)日：2020-01-23
申请号：US16240389
申请日：2019-01-04
IPC分类号： A61K31/5377 , A61K31/00
摘要： The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity.
-
公开(公告)号：US20190201407A1
公开(公告)日：2019-07-04
申请号：US16297194
申请日：2019-03-08
CPC分类号： A61K31/5375 , A61K9/00 , A61K9/146 , A61K9/2054 , A61K9/485 , A61K9/4866 , A61K9/50
摘要： Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.
-
公开(公告)号：US10201547B2
公开(公告)日：2019-02-12
申请号：US16046858
申请日：2018-07-26
IPC分类号： A61K31/5377 , A61K31/00
摘要： The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity.
-
-
-
-
-
-
-
-
-
搜索结果
123 条记录 (耗时 0.033 秒)
